Micronutrient Blend Reduces Homocysteine 23% and VEGF 47% in Diabetic Retinopathy with MTHFR Polymorphisms

Diabetic retinopathy (DR), a leading cause of blindness, is characterized by microvascular damage driven by disturbances in one-carbon metabolism, endothelial signaling, and oxidative stress. Elevated homocysteine levels, often exacerbated by MTHFR polymorphisms, impair endothelial function and promote angiogenesis via VEGF. Current treatments primarily target advanced stages, leaving a gap for early intervention strategies that modulate these underlying metabolic and vascular pathways to prevent disease progression.

This 6-month pilot study enrolled ten patients diagnosed with type 2 diabetes, mild diabetic retinopathy, and confirmed MTHFR polymorphisms. Participants received daily targeted micronutrient supplementation, including L-methylfolate, methylcobalamin, pyridoxal-5'-phosphate, antioxidants, and thiol donors. The primary endpoints assessed were serum homocysteine, plasma VEGF, and D-dimer levels, measured to evaluate modulation of one-carbon metabolism, endothelial function, and coagulation balance. No control group was included in this exploratory design.

Micronutrient supplementation was associated with significant shifts in key biomarkers. Serum homocysteine levels decreased by 23%, indicating successful modulation of homocysteine remethylation. Plasma VEGF, a critical angiogenic factor in DR, saw a substantial 47% reduction.

These findings suggest biochemical engagement of relevant vascular pathways, with a 23% reduction in serum homocysteine and a 47% decrease in plasma VEGF. However, D-dimer levels, a marker of fibrin turnover, increased by 15%. While this increase is mechanistically consistent with enhanced fibrin clearance, the abstract notes that D-dimer elevations alone cannot distinguish this from increased thrombotic risk, highlighting a need for more comprehensive coagulation assessment.